Kornimate/medical-research-clean huggingface dataset:
the detect hcv linkage to care trial

Conditions: Hepatitis C

Summary: this aim of the detect hcv linkage trial compares two linkage to care intervention strategies among (1) newly diagnosed hcv positive patients from the emergency department (ed) and (2) those patients who present to the ed with untreated active hcv. patients who are positive for hcv and agree to be part of the study will be randomized to either clinician referral alone or clinician referral plus a linkage navigator.

the investigators will perform a prospective pragmatic randomized effectiveness trial to compare 2 linkage-to-care strategies. permuted block randomization with 2 strata (i.e., \<40 years of age or active idu \[defined as idu within 30 days\], or ≥40 years of age without active idu) and varying block sizes will be used to minimize imbalance, ensure appropriate numbers of patients in subgroups, and allow for efficient analyses. allocation will be concealed by blinding block sizes and using the redcap randomization module, a web-based platform to assign patients to arms (redcap, vanderbilt university, tn). although patients will not be blinded to the interventions, they will be blinded to the outcomes. also, a trained research assistant will perform all enrollment, including stratification and randomization. clinical staff will not be blinded, however, to assignment.

Eligibility criteria:
inclusion criteria: * ed patients who test positive for hcv antibodies * ed patients who have discharged and confirmatory rna result is positive * clinically stable per screening nurse or physician assessment * able to provide consent * ed patients with untreated active hcv confirmed by the electronic medical record exclusion criteria: * younger than 18 years of age * prisoners * pregnant women * individuals that live out of state * unable to consent for care (e.g., altered mentation, critical illness or injury) * non english or spanish speaking * have already participated in the trial
effectiveness of the myofascial therapy in the hemophilic arthropathy of ankle

Conditions: Haemophilia

Summary: randomized clinical trial to assess the efficacy of a treatment protocol applied fascial therapy in patients with hemophilic arthropathy ankle, oriented to know and describe the observed differences on the dependent variables: range of motion, pain and physical condition. at the same time, the study will determine whether there are adverse effects or bleeding complications as a result of applied physiotherapy treatment.


Eligibility criteria:
inclusion criteria: * patients diagnosed with hemophilia a and b * adults patients * patients with hemophilic arthropathy of ankle diagnosed * patients in prophylactic treatment regimen or on demand treatment with concentrates of fviii/fix. exclusion criteria: * patients without ambulation * patients diagnosed with other congenital coagulopathy (eg, von willebrand disease) * patients who have developed antibodies to fviii / fix (inhibitors) * patients with neurological or cognitive impairments that prevent understanding of questionnaires and test physical * patients that have not signed the informed consent document.

Keywords: haemophilia ankle arthropathy pain range of motion myofascial techniques
socioeconomic behavior changes during the pandemic

Conditions: Pandemic, COVID-19; Sedentary Behavior

Summary: the goal of this observational study was to determine the changing shopping and movement habits of people during the period of march 2020- june 2021, when full and partial lockdown measures were in force due to the covid 19 outbreak in our country. in 500 adult participants. the main questions were: * whether the increase in sedentaryism that occurred during the pandemic will persist after the pandemic ended? * whether the socioeconomic behavior patterns that emerged during the pandemic period will persist after the pandemic?

a questionnaire was created by experts in order to examine the predicted changes with a numerical tool and on large audiences. totally, 765 adult individuals (452 female, 313 male) answered the questionnaire. in the created questionnaire, it was envisaged to evaluate the changes by asking demographic data, shopping habits, exercise habits and health problems in the pre-closure period, closure period and post-closure period. in order to determine the changing shopping habits of the participants, they were asked what type of shopping they did and how often, face to face and online, before the closure period (before march 2020), during the closure period (march 2020- june 2021) and after the closure period up to 2 years (june 2021-june 2023). a 5-point likert scale was used to determine shopping frequency, with questions ranging from 1 for never; and 5 for allways. shopping types are listed as daily materials (grocery shopping), clothing, electronics, cosmetics - personal care products, household goods - furniture, ready-made food (food ordering at home) and gifts - toys. to determine the sedentary tendency of the participants, movement habits that distract from sedentary life were grouped under three headings. these were determined as weekly active sports activities, weekly non-sports activities that are expected to require movement, and the number of daily steps. in the prepared questionnaire, participants were asked before the closure period (before march 2020), during the closure period (march 2020- june 2021) and after the closure up to 2 years (june 2021-june 2023); which sports they engage in and their total active sports time; they were asked which non-sport activities they engaged in, their total non-sport activity time and daily step count. in order to determine the health problems of the participants, if any, they were asked about the health problems they experienced before the closure period (before march 2020), during the closure period (march 2020- june 2021) and after the closure period up to 2 years (june 2021-june 2023).

Eligibility criteria:
inclusion criteria: * ≥18 years old * all genders

Keywords: pandemic socioeconomic behavioral changes sedentaryism
the acute effects fortified nutritional supplementation on childhood cognition

Conditions: Cognitive Ability, General; Dietary Modification

Summary: the aim of this study is to investigate the acute effects of ingestion of carbohydrates - with different glycemic profiles - on cognitive function among preadolescent children (i.e., 9-10 years).

regular breakfast consumption is linked to improved cognitive performance in school-aged children. however, the acute benefits of defined nutrient consumption on brain and cognitive health are not well understood, particularly in preadolescent children. one factor that may relate to brain health and learning in children is the contribution of carbohydrates to the digestion rate of a meal (and associated effects on post-prandial glycemia). the effects of differentially absorbed carbohydrates on brain and cognition are unknown, especially when ingested via a fortified nutritional beverage providing a balanced array of nutrients. the aim of this study is to investigate the acute, transient effect of nutrient supplementation with varied carbohydrate systems in preadolescent children (i.e., 9-10 years). participants will be randomized to receive one of three treatment nutritional formulations containing carbohydrates with varying absorption rates along with a non-caloric placebo. participants will perform a cognitive battery in the fasted condition, shortly after treatment ingestion, and an hour after ingestion. group differences in performance will be contrasted to assess the effects of different carbohydrate types on children's cognitive function following an overnight fast. findings from this study will inform our understanding of the macronutrient profile of breakfast that may potentially improve children's cognitive performance in the morning.

Eligibility criteria:
inclusion criteria: * parental/guardian consent. * participants must be between the ages of 9-10 years old at the time of testing age * normal or corrected-to-normal vision based on the minimal 20/20 standard in order to complete the cognitive task (below 20/20 vision). * participants must have an iq \> 85 (iq \< 85). exclusion criteria: * prior diagnosis of cognitive or physical disability, including adhd (severe asthma, epilepsy, and dependence upon a wheelchair/walking aid, and adhd rating scale score below 85%). * use of anti-psychotic, anti-depressant, anti-anxiety medication, as well as those medications used for add/adhd (use of any anti-psychotic, anti-depressant, anti-anxiety, and add/adhd medications). * early pubertal status, as measured by a modified test of the tanner staging system (onset of puberty as determined by tanner). * lactose intolerance * allergies to milk and/or soy * adherence to a strict vegan diet
the role of intravenous (iv) lidocaine in the management of chronic neuropathic pain of peripheral nerve origin

Conditions: Neuropathic Pain

Summary: pain as a result of nerve injury (neuropathic pain) is a particularly severe form of chronic pain. common examples of neuropathic pain are pain due to diabetes and shingles. there is good evidence that an intravenous infusion of lidocaine (local anesthetic) is useful for the management of neuropathic pain in the short term - up to six hours.

this study will examine the role of intravenous lidocaine in the relief of neuropathic pain over four weeks following infusion compared to an active placebo infusion of diphenhydramine(benadryl) in normal saline. if we can show that intravenous lidocaine provides sustained benefit for up to one month, this will be a major advance in the management of individuals suffering from neuropathic pain.

Eligibility criteria:
inclusion criteria: * chronic neuropathic pain due to diabetes mellitus or herpes zoster and a score of 4/10 or greater on the dn4 questionnaire. * moderate to severe pain as defined by screening average pain intensity of 5 or greater on a 0-10 numerical rating scale. * neuropathic pain duration of at least 6 months. exclusion criteria: * presence of clinically significant cardiac disease. * poorly controlled seizure disorder. * significant psychiatric disorder. * history of allergy to lidocaine or any other amide local anesthetic * history of allergy to diphenhydramine. * prior treatment with a local anesthetic infusion. * neuropathic pain due to cancer or complex regional pain syndrome * language barrier or cognitive impairment that would preclude understanding of the study and filling out of questionnaires * lack of a driver to transport the patient to and from the pain clinic.
a novel approach for alleviating the side effects of chemotherapeutic agents.

Conditions: Breast Cancer; Lung Cancer; Prostate Cancer

Summary: this study will assess the effectiveness of a natural nutraceutical in treating the known side effects of chemotherapeutic agents in cancer patients.

this study will assess the effectiveness of a natural nutraceutical in treating the known side effects of chemotherapeutic agents in cancer patients. the study will be observing the standard treatment protocol for any degradation or enhancement due to the nutraceutical.

Eligibility criteria:
inclusion criteria: active breast cancer patients taking one of the studies listed drugs within the age range. active lung cancer patients taking one of the studies listed drugs within the age range. active prostate cancer patients taking one of the studies listed drugs within the age range. - exclusion criteria: anyone without the three types of cancer (breast cancer, lung cancer, prostate cancer) listed in inclusion criteria. -

Keywords: cancer breast lung prostate
multifactorial approach associated with orlistat (xenical) for 4 years weight loss maintenance in obese adults

Conditions: Obesity

Summary: this study will evaluate the efficacy of a multifactorial approach associated with orlistat (xenical) in weight loss maintenance during 4 years. the effect of orlistat in combination with diet, physical activity, and/or cognitive behavioral therapy will be monitored.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) greater than or equal to (\>/=) 30 kilograms per meter-squared (kg/m\^2), or bmi \>/= 28 kg/m\^2 with risk factors of diabetes, hypertension, or hyperlipidemia, before weight loss * documented weight loss \>/= 10% of initial body weight obtained with diet, with or without psychological therapy or orlistat exclusion criteria: * pregnant or lactating females * history or presence of significant medical disorders * active gastrointestinal disorders such as peptic ulcer disease or malabsorption syndromes * pancreatic disease: pancreatic enzyme deficiency, history or current presence of pancreatitis * clinically significant abnormal clinical chemistry or hematology results * excessive alcohol intake * smoking cessation within the previous 6 months * history or presence of cancer * administration of medicines known to alter body weight * history or presence of cancer
air-q and proseal laryngeal mask in elderly patients

Conditions: Postoperative Complications; Sore Throat

Summary: aged- related changes in upper airway anatomy may affect the overall performance of supraglottic airways significantly. in this study, investigator aim to compare the clinical performance, efficacy, and associated complications of the proseal laryngeal mask and the air-q intubation laryngeal airway in elderly patients.

elderly patients are vulnerable to perioperative pulmonary complications during intubation and extubation. supraglottic airway devices (sads) have been utilized as a relatively easy method of airway management for resuscitation and difficult intubations and are used during elective general anesthesia with reduced airway complications compared to endotracheal intubation. sads may help maintain hemodynamic stability as they require less anesthetic agents compared to endotracheal intubation. with aging, parapharyngeal fat accumulation increases, leading to pharyngeal collapse in elderly patients. additionally, structural changes in the respiratory tract combined with physiological alterations in respiration may reduce oxygen saturation, blunt the hypoxic response, and increase postoperative respiratory complications. acquired changes in pharyngeal muscle activity with age are thought to increase the likelihood of bony structural changes, such as retrognathia, which is typically considered a difficult airway. therefore, these age-related changes may impact the clinical performance of sads. proseal lma is one of the most commonly used supraglottic airway devices in clinical practice. it was developed by modifying the classic lma in the 2000s and features an inflatable cuff. additionally, it has a gastric channel for gastric aspiration adjacent to the airway tube. recently, sgas (supraglottic airways) that do not require manual cuff inflation have been increasingly used in various clinical situations due to the advantages of eliminating manual cuff inflation and monitoring cuff pressure. air-q connects to an airway tube via a communication port that allows self-regulation of cuff pressure in response to airway pressure. in this study, investigator aim to compare the clinical performance, efficacy, and associated complications of the proseal laryngeal mask and the air-q intubation laryngeal airway in elderly patients.

Eligibility criteria:
inclusion criteria: * 65-90 year-old patients * american society of anesthesiologist physical status classification i-iii, * undergoing an elective operation under general anesthesia in our hospital exclusion criteria: * predicted difficult airway (mallampati class 4, mouth opening \< 3 cm, or thyromental distance \< 6 cm) * body mass index (bmi) \> 40 kg/m2 * patients with a high risk of aspiration (e.g., history of gastrectomy, -gastroesophageal reflux disease, or hiatal hernia), * unstable vital signs * cervical spine problems, respiratory complications (e.g. recent pneumonia).

Keywords: air-q laryngeal i̇ntubating airway oropharyngeal leak pressure proseal larygeal mask supraglottic airways
performance of an investigational blood glucose monitoring system in a clinical setting

Conditions: Diabetes

Summary: the purpose of this study is to evaluate the performance and acceptability of an investigational blood glucose monitoring system, which includes meter and sensor strip.


Eligibility criteria:
inclusion criteria: * males and females, 18 years of age and above * type 1 or type 2 diabetes * currently self-testing blood glucose at home at least twice daily * able to speak, read, and understand english * willing to complete all study procedures exclusion criteria: * currently pregnant * hemophilia or any other bleeding disorder * employee of competitive medical device company * cognitive disorder or other condition which, in the opinion of the investigator, would put the person at risk or seriously compromise the integrity of the study
hypnosis in reducing pain and other side effects in women undergoing surgery for breast cancer

Conditions: Anxiety Disorder; Breast Cancer; Nausea and Vomiting; Pain

Summary: rationale: hypnosis may be effective in reducing pain and other side effects in women undergoing surgery for breast cancer. purpose: this clinical trial is studying how well hypnosis works in reducing pain and other side effects in women undergoing surgery for breast cancer.

objectives: * to test the feasibility of hypnosis as a pre-operative intervention for the reduction of surgical- and anesthesia-related symptoms in women undergoing lumpectomy with sentinel node biopsy, mastectomy, or mastectomy with lymph node dissection for locally recurrent breast cancer. * to identify the physical symptoms (i.e., pain, nausea, and vomiting) and psychological symptoms (i.e., anxiety and distress) of patients undergoing hypnosis. * to determine the length of stay in the post anesthesia care unit of patients undergoing adjunct hypnosis. * to describe patient satisfaction with the hypnosis experience. * to determine the effect size and calculate the sample needed for a randomized clinical trial using the results of this study. outline: patients undergo a scripted hypnotic intervention over 15 minutes within 1 hour prior to their planned surgical procedure. upon completion of the intervention, patients proceed to the preoperative holding area of the surgery and post anesthesia care unit where they receive the standard of care for lumpectomy with sentinel node biopsy, mastectomy, or mastectomy with lymph node dissection. patients undergo collection of demographic information (i.e., age; gender; ethnicity; marital/partnered status; spiritual practice; family members in the home; stress management history; experience with the continuum of imagery/hypnosis practices; perceptions of concentration abilities; and favorite aromas, colors, and scenes from nature) at the time of consent using the demographic survey questionnaire. they also undergo assessment of physical and psychological symptoms (i.e., pain, nausea, vomiting, anxiety, and generalized distress) at baseline (immediately prior to hypnotic induction) and after the intervention (prior to discharge from the post anesthesia care unit).

Eligibility criteria:
disease characteristics: * diagnosis of breast cancer * scheduled for breast surgery (i.e., lumpectomy with sentinel node biopsy, mastectomy, or mastectomy with lymph node dissection) with dr. garbaroglio * hormone receptor status not specified patient characteristics: * menopausal status not specified * able to speak and read english * able to follow instruction * no uncontrolled major comorbid mental conditions (i.e., thought disorders) * no uncontrolled major physical conditions (i.e., untreated congestive heart failure) prior concurrent therapy: * see disease characteristics * no concurrent reconstruction surgery

Keywords: anxiety disorder pain nausea and vomiting breast cancer
a study of telitacicept for the treatment of moderately to severely active systemic lupus erythematosus (remesle-2)

Conditions: Systemic Lupus Erythematosus

Summary: the purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active sle.

systemic lupus erythematosus (sle) is a chronic autoimmune disease with heterogeneous manifestations and disease course. despite advances in medical care, there are still significant unmet needs in sle with diminished health-related quality of life (hrqol), persistent disease activity, disease flares, intolerance to standard of care (soc) therapies, and development of organ damage and co-morbidities. telitacicept is a fully human taci-fc fusion protein that targets b lymphocyte stimulator (blys) and a proliferating-inducing ligand (april). blocking the interaction of blys and april with their cell membrane receptors (taci, b-cell maturation antigen (bcma), and b-cell activating factor receptor (baff-r) would inhibit b cell proliferation and maturation, suppresses immune responses and may alleviate autoimmune symptoms. this is a multicenter, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of telitacicept added to standard of care (soc) therapy compared to placebo with soc therapy in subjects with moderately to severely active sle.

Eligibility criteria:
inclusion criteria: 1. age 12-70 years at screening. 2. has a diagnosis of sle for at least 6 months prior to the screening visit. 3. meets the 2019 eular/acr classification criteria for sle. 4. moderately to severely active sle definined by the following: 1. selena sledai total score ≥6 points with clinical sledai score ≥4 points at screening; 2. bilag organ system scores of at least 1a or 2b at screening. 5. clinical sledai score of ≥4 at day 0 prior to randomization. 6. at least one positive serologic parameter within the screening period. 7. currently receiving at least one of the soc sle medications: oral corticosteroid, antimalarial and/or immunosuppressive agent. exclusion criteria: 1. active lupus nephritis undergoing induction therapy or unstable renal diseases within 12 weeks prior to screening. 2. active or unstable neuropsychiatric sle. 3. autoimmune or rheumatic disease other than sle. 4. history of arterial or venous thromboembolism or microangiopathy within 12 months prior to screening. 5. history of non-sle disease requiring treatment with oral or parenteral. glucocorticosteroids for more than a total of 2 weeks within the last 24 weeks prior to screening.

Keywords: systemic lupus erythematosus sle